ACM
CLDX icon

Aster Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Aster Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,014
Closed -$26.2K – 1144
2025
Q3 		$26.2K Buy
+1,014
New +$23.5K 0.01% 626
2025
Q2 		– Sell
-1,446
Closed -$29.7K – 1117
2025
Q1 		$29.7K Buy
1,446
+1,256
+661% +$28.1K 0.01% 920
2024
Q4 		$4.8K Buy
+190
New +$5.16K ﹤0.01% 863

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Aster Capital Management's CLDX Position: Q4 2025 in Review

Aster Capital Management sold out of Celldex Therapeutics (CLDX) in Q4 2025, closing a stake of 1,014 shares — an estimated $26.2K sold.

Aster Capital Management first reported a position in CLDX in Q4 2024 and held it in 3 quarters. The position peaked at $29.7K in Q1 2025. 185 funds tracked by Wall St. Rank hold CLDX as of Q4 2025.

  • Aster Capital Management reported no remaining Celldex Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Aster Capital Management sold 1,014 Celldex Therapeutics shares in Q4 2025, an estimated $26.2K.
  • Aster Capital Management first reported a position in Celldex Therapeutics in Q4 2024 and held it in 3 quarters.
  • Aster Capital Management's Celldex Therapeutics position peaked at $29.7K in Q1 2025.
  • 185 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2025.

Based on Aster Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.